- Home
- TBHC vs SKYE Comparison
TBHC vs SKYE Comparison
Compare TBHC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBHC | SKYE |
|---|---|---|
| Founded | 1966 | 2012 |
| Country | United States | United States |
| Employees | 4010 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 24.2M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | TBHC | SKYE |
|---|---|---|
| Price | $0.92 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 71.7K | ★ 196.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $0.57 |
| 52 Week High | $2.40 | $5.75 |
Technical Indicators
Market Signals| Indicator | TBHC | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 53.53 |
| Support Level | N/A | $0.68 |
| Resistance Level | $1.27 | $0.83 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 47.00 | 87.16 |
Price Performance
Historical ComparisonAbout TBHC The Brand House Collective Inc.
The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.